Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on aTyr Pharma and keeping the price target at $16.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Faisal Khurshid has given his Buy rating due to a combination of factors, primarily focusing on the potential of aTyr Pharma’s efzofitimod in treating pulmonary sarcoidosis. The upcoming Phase 3 EFZO-FIT readout is considered highly binary, with a significant probability of success estimated at 60%. This presents a high-risk, high-reward scenario, with potential stock price movements of +200-300% on success or -80% on failure. Despite some unanswered questions regarding the underlying science and clinical data, Khurshid sees a decent chance of success and favors the risk/reward balance.
Additionally, upcoming MEDACorp KOL events are expected to provide valuable insights and context ahead of the readout. These events will feature key opinion leaders with firsthand experience using efzofitimod, offering opportunities for investors to engage directly and clarify expectations. The interpretation of Phase 1/2 data, which showed dose-dependent clinical benefits, will be crucial, although it is complicated by small sample sizes and methodological differences. Overall, Khurshid reiterates an Outperform rating, emphasizing the promising outlook for efzofitimod’s clinical development.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.